|

HLD-0915 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Halda Therapeutics OpCo, Inc.1

Indications

  • Prostate Cancer Metastatic Disease1
  • Prostate Cancer (Adenocarcinoma)1
  • Cancer1

Denver, Colorado1 trial

A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Sarah Cannon Research Institute at HealthONE

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.